TLPPF (Telix Pharmaceuticals) Future Policy Benefits

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TLPPF Telix Pharmaceuticals Ltd TLPPF
70 GF Score
Price $11.95
GF Value $23.89
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Telix Pharmaceuticals Future Policy Benefits?

Future Policy Benefits only applies to insurance companies.

TLPPF
70GF Score
Telix Pharmaceuticals Ltd TLPPF
Future Policy Benefits is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Telix Pharmaceuticals (TLPPF) Overvalued in 2026?

Based on GuruFocus' analysis, Telix Pharmaceuticals stock appears to be undervalued. The current stock price of $11.95 is trading 50% below its estimated GF Value™ of $23.89. GuruFocus considers Telix Pharmaceuticals to be Possible Value Trap.

Key valuation signals for TLPPF:

  • Future Policy Benefits:
  • GF Value™: $23.89 vs. price of $11.95 (50% below fair value)
  • GF Score™: 70/100 with 7 warning signs

No single metric tells the full story. See the TLPPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Telix Pharmaceuticals Business Description

Address 55 Flemington Road, Level 4, North Melbourne, Melbourne, VIC, AUS, 3051
Telix Pharmaceuticals is an Australian radiopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic products for cancer and other diseases. Its lead commercial product, Illuccix (gallium-68 PSMA-11), is a positron emission tomography imaging agent used to visualize prostate cancer, and it generates the majority of the company's revenue through sales in the United States, where it is also developing Gozellix, a next-generation prostate cancer imaging agent. Telix's pipeline spans urology, oncology, and rare diseases, including both diagnostic imaging agents and therapeutic radioligand candidates, along with adjunct products such as bone marrow conditioning and kidney protection agents. The company sells primarily to nuclear medicine clinics, hospitals, and imaging centers, and is expanding its commercial footprint across the United States, Europe, and other international markets through direct sales and partnerships.
70GF Score

Get the complete analysis for TLPPF

Future Policy Benefits is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.95
Price
$23.89
GF Value